10 unknown, 9 completed, 4 recruiting, 3 terminated. 28 Phase 3, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 28 | Unknown 10, Completed 9, Recruiting 4, Terminated 3, Active not recruiting 1, Not yet recruiting 1 |
| Phase 2 | 5 | Unknown 2, Completed 1, Recruiting 1, Terminated 1 |
Follow Tegafur: new trials by email Literature Review of Tegafur trials Research Report on Tegafur
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction Adenocarcinoma tegafur, Gimeracil and Oteracil Potassium Capsules, Sintilimab Placebo, Sintilimab - Resectable Gastric/Gastroesophageal Junction Adenocarcinoma | Phase 2 / Phase 3 | Recruiting | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | 720 | 2026-07-31 | 2026-08-14 |
| Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer GFH375, Chemotherapy - Metastatic Pancreatic Cancer | Phase 3 | Recruiting | Genfleet Therapeutics (Shanghai) Inc. | 320 | 2025-12-04 | 2026-08-14 |
| Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) Rilvegostomig, Placebo, Capecitabine - Biliary Tract Cancer | Phase 3 | Active not recruiting | AstraZeneca | 760 | 2023-12-04 | 2026-10-16 |
| Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer Envolimab, Fruquintinib, Oxaliplatin - Gastric Cancer | Phase 3 | Not yet recruiting | Fujian Medical University | 100 | 2023-09-01 | 2023-08-25 |
| Toripalimab Plus Radiotherapy for Elderly Esophageal Cancer Patients Treated With Non-chemotherapy Strategy Toripalimab, Tegafur, IMRT - Esophageal Cancer, Radiation Therapy | Phase 2 / Phase 3 | Unknown | Taizhou Hospital | 60 | 2022-07-01 | 2023-04-18 |
| Study of Tislelizumab in Combination With SOX for the Treatment of Gastric Cancer With Liver Metastases Tislelizumab in Combination with Oxaliplatin and Tegafur - Liver Metastases | Phase 2 / Phase 3 | Unknown | Zhejiang University | 40 | 2022-04-10 | 2023-02-01 |
| Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer Lerotinib, Irinotecan/Tegafur - Esophageal Cancer | Phase 3 | Recruiting | Sunshine Lake Pharma Co., Ltd. | 416 | 2021-01-21 | 2026-09-28 |
| Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer nab paclitaxel, Tegafur, Oxaliplatin - Stomach Cancer | Phase 3 | Unknown | Zhejiang Cancer Hospital | 616 | 2020-03-01 | 2020-03-23 |
| S-1 for 9 Months Versus 1 Year for Stage II Gastric Cancer (SMAC) S-1 for 9 months, S-1 for 1 year - Gastric Cancer | Phase 3 | Recruiting | Fudan University | 1006 | 2019-01-01 | 2019-05-31 |
| A Study of Intraperitoneal Paclitaxel in Combination With SOX Compared With SOX Alone in Gastric Cancer With Malignant Ascites Oxaliplatin, Paclitaxel, S-1 (Tegafur, Gimeracil and Oteracil Porassium Capsules) - Gastric Cancer, Stomach Neoplasms | Phase 3 | Unknown | Fudan University | 215 | 2018-03-16 | 2018-03-23 |
| A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA MEP - Nasopharyngeal Carcinoma | Phase 3 | Terminated | National Health Research Institutes, Taiwan | 10 | 2014-12-14 | 2025-08-19 |
| Perioperative Chemotherapy for Potentially Resectable Gastric Cancer Tegafur, Gimeracil and Oteracil Potassium Capsules;Oxaliplatin, Oxaliplatin; Capecitabine - Gastric Cancer | Phase 2 / Phase 3 | Completed | Hebei Medical University | 749 | 2012-02-01 | 2020-02-13 |
| Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer Docetaxel (XRP6976), Oxaliplatin (SR96669), S-1 (1-(2-tetrahydrofuryl)-5-fluorouracil + 5-chloro-2, 4-dihydroxypyridine (CDHP) (Gimeracil) + Oxo (Oteracil) - Gastric Cancer | Phase 3 | Completed | Sanofi | 530 | 2011-12-30 | 2023-12-13 |
| Trial of S-1 Plus Cisplatin in Gastric Cancer s-1 plus cisplatin, 5-Fu plus cisplatin - Gastric Cancer | Phase 3 | Unknown | Sun Yat-sen University | 270 | 2008-09-01 | 2011-07-25 |
| Tegafur-Uracil and Leucovorin or S-1 in Treating Patients With Stage III Colon Cancer That Has Been Completely Removed by Surgery folinate calcium, tegafur-uracil, tegafur-gimeracil-oteracil potassium - Colorectal Cancer | Phase 3 | Completed | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | 1535 | 2008-04-01 | 2016-08-03 |
| Uracil and Tegafur/Leucovorin (UFT/LV) Versus UFT/LV+ Polysaccharide-K (PSK) for Stage IIIa/IIIb Colorectal Cancer UFT, Calcium Folinate, PSK, UFT, Calcium Folinate - Colorectal Cancer | Phase 3 | Unknown | Iwate Medical University | 300 | 2007-07-01 | 2008-07-31 |
| Phase II Study of TS-1 Therapy and TS-1+PSK Therapy Against Advanced Gastric Carcinoma Tegafur/gimeracil/oteracil potassium (S-1), Krestin (PSK), Tegafur/gimeracil/oteracil potassium (S-1) - Gastric Cancer | Phase 2 / Phase 3 | Terminated | Eastern Network of Cancer Immunological Therapy, Japan | 13 | 2006-10-01 | 2009-01-23 |
| Tegafur-Uracil or Observation in Treating Patients With Stage II Colorectal Cancer That Has Been Completely Removed By Surgery UFT adjuvant chemotherapy - Colorectal Cancer | Phase 3 | Completed | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | 2025 | 2006-10-01 | 2016-09-28 |
| S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck Cancer tegafur-gimeracil-oteracil potassium, tegafur-uracil, adjuvant therapy - Head and Neck Cancer | Phase 3 | Unknown | Yokohama City University | 500 | 2006-04-01 | 2013-05-15 |
| A Phase III Trial Comparing UFT+PSK to UFT+LV in Stage IIB, III Colorectal Cancer Tegafur-uracil (UFT), Calcium folinate (LV), Krestin (PSK) - Colorectal Cancer | Phase 3 | Unknown | Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group | 380 | 2006-03-01 | 2012-10-26 |
Showing 20 of 28. Sign in to see all of them.
Stomach Neoplasms (10) · Colorectal Neoplasms (7) · Colonic Neoplasms (3) · Breast Neoplasms (2) · Esophageal Neoplasms (2) · Rectal Neoplasms (2) · Bile Duct Neoplasms (1) · Biliary Tract Neoplasms (1) · Cholangiocarcinoma (1) · Epstein-Barr Virus Infections (1) · Gallbladder Neoplasms (1) · Head and Neck Neoplasms (1) · Klatskin Tumor (1) · Lung Neoplasms (1) · Nasopharyngeal Carcinoma (1)
Taiho Pharmaceutical Co., Ltd. (4) · Fudan University (2) · Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan (2) · AstraZeneca (1) · Eastern Network of Cancer Immunological Therapy, Japan (1) · Fujian Medical University (1) · Genfleet Therapeutics (Shanghai) Inc. (1) · Hebei Medical University (1) · Hokkaido Gastrointestinal Cancer Study Group (1) · Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. (1) · Institut Cancerologie de l'Ouest (1) · Iwate Medical University (1) · Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group (1) · NSABP Foundation Inc (1) · National Health Research Institutes, Taiwan (1)
Japan (13) · China (11) · France (2) · South Korea (2) · Taiwan (2) · Australia (1) · Belgium (1) · Brazil (1) · Canada (1) · Denmark (1) · Germany (1) · Hong Kong (1) · India (1) · Italy (1) · Norway (1)
Kenichi Sugihara, MD, PhD (2) · Chia-Jui Yen Yen, MD. PhD (1) · Ching-Yun Hsieh, MD (1) · Christian Chevelle, MD (1) · Dazhi Xu, PHD, MD (1) · Go Wakabayashi, MD, PhD (1) · Hideaki Tahara, MD (1) · Hirohito Tada, MD (1) · Hiroki Koyama, MD (1) · Hsiao-Hui Tsou, PhD (1) · JianMing Xu, Doctor (1) · Jin-Ching Lin, MD, PHD (1) · Jin-Ching Lin, MD, PhD (1)
PMID 11098486, PMID 16648506, PMID 16675478, PMID 16945170, PMID 17264338, PMID 17948223, PMID 19204202, PMID 19638976, PMID 22769569, PMID 24942277, PMID 25671770, PMID 26439700, PMID 29677641, PMID 30425843, PMID 31180819, PMID 32583567, PMID 33435909, PMID 34133211, PMID 37501640, PMID 38996201
2023 (1), U10CA012027 (1)